Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone

被引:0
|
作者
M. Alberghini
K. Kliskey
T. Krenacs
P. Picci
L. Kindblom
R. Forsyth
N. A. Athanasou
机构
[1] Istituto Ortopedico Rizzoli,Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
[2] University of Oxford,1st Department of Pathology and Experimental Cancer Research
[3] Semmelweis University,undefined
[4] Royal Orthopaedic Hospital,undefined
[5] N. Goormaghtigh Institute of Pathology,undefined
来源
Virchows Archiv | 2010年 / 456卷
关键词
Giant cell; Bone tumour; Osteoclast; Metastasis;
D O I
暂无
中图分类号
学科分类号
摘要
Giant cell tumour of bone (GCTB) is a primary tumour of bone that may rarely, in the absence of malignant cytological features, produce metastatic lesions, most commonly in the lungs. Whether these lung nodules represent true neoplastic secondaries or implants derived from the primary tumour is not certain. In this study, we have analysed the morphological and immunophenotypic features of 19 conventional GCTBs and corresponding lung nodules for expression of macrophage, osteoclast, proliferation and tumour-associated markers. A striking morphological feature of all GCTBs that produced lung secondaries was the presence of large areas of haemorrhage and thrombus formation; mononuclear and multinucleated cells of GCTB were frequently found within these areas of haemorrhage and thrombus. A similar pattern of CD14, CD33, HLA-DR and CD51 expression was seen in macrophages and giant cells in primary and secondary tumours. Smooth muscle actin expression was frequently noted in primary GCTBs that recurred and metastasised. No difference was seen in the expression of p53, p63, Ki-67, cyclin D1 or Bcl-2 in primary and secondary tumours. Our findings suggest that most lung nodules associated with primary conventional GCTBs are implants derived from tumour emboli formed in areas of haemorrhage and thrombus formation within the primary tumour.
引用
收藏
页码:97 / 103
页数:6
相关论文
共 50 条
  • [31] Treatment of giant-cell tumour of bone
    Elmslie, RC
    BRITISH MEDICAL JOURNAL, 1937, 1937 : 431 - 432
  • [32] GIANT-CELL TUMOUR (OSTEOCLASTOMA) OF BONE
    BARRY, HC
    JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1962, 44 (03): : 748 - 749
  • [33] Denosumab treatment of giant cell tumour of bone
    Balke, Maurice
    LANCET ONCOLOGY, 2013, 14 (09): : 801 - 802
  • [34] Telomere biology in giant cell tumour of bone
    Forsyth, R. G.
    De Boeck, G.
    Bekaerl, S.
    De Meyer, T.
    Taminlau, A. H. M.
    Uyttendaele, D.
    Roels, H.
    Praet, M. M.
    Hogendoorn, P. C. W.
    JOURNAL OF PATHOLOGY, 2008, 214 (05): : 555 - 563
  • [35] Radiosensitive giant cell tumour of the sphenoid bone
    Kishima, H
    Miyao, Y
    Shimizu, K
    BRITISH JOURNAL OF NEUROSURGERY, 2001, 15 (02) : 171 - 174
  • [36] Treatment of giant-cell tumour of bone
    Brailsford, JF
    BRITISH MEDICAL JOURNAL, 1937, 1937 : 554 - 554
  • [37] Metachronous multicentric giant cell tumour of bone
    Vangala, Navatha
    Uppin, Shantveer G.
    Ayesha, Sobiya Mehnaz
    Harshavardhana, K. R.
    Chandrasekhar, P.
    SKELETAL RADIOLOGY, 2018, 47 (11) : 1559 - 1566
  • [38] OSTEOCLASTOMA OR GIANT-CELL TUMOUR OF BONE
    PLATT, H
    JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1949, 31 (02): : 157 - 158
  • [39] Treatment of giant-cell tumour of bone
    Osborn, GR
    BRITISH MEDICAL JOURNAL, 1937, 1937 : 553 - 554
  • [40] Giant cell tumour of bone in the denosumab era
    van der Heijden, Lizz
    Dijkstra, P. D. Sander
    Blay, Jean-Yves
    Gelderblom, Hans
    EUROPEAN JOURNAL OF CANCER, 2017, 77 : 75 - 83